Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or at risk for HBV reactivation.
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration
No known chronic active liver disease or evidence of acute or chronic hepatitis B virus (HBV) or hepatitis C (HCV)
Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening
Active hepatitis B virus (HBV) infection
Active hepatitis B virus (HBV) or hepatitis C (HCV) infection;
Known or suspected chronic active Epstein-Barr virus (EBV) infection, acute or chronic hepatitis C virus (HCV) infection
Patients who have a clinically active hepatitis B or C virus infection are not eligible; NOTE: those with documented evidence of past exposure to hepatitis B virus (HBV) or hepatitis C virus (HCV) may enroll so long as the respective viral load is negative AND subject is willing/able to take appropriate antiviral prophylaxis to prevent reactivation
Patients are not eligible who have clinically active hepatitis B (tested at screening) or known hepatitis A or C infections;\r\n* NOTE: Patients with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection may enroll if other laboratory criteria are met; those with HBV surface antigen positivity may enroll only if maintained on appropriate suppressive antiviral therapy, per treating investigatorâ€™s discretion, for the duration of enrollment in the trial
Active hepatitis B virus (HBV) infection (chronic or acute)
Active hepatitis C virus (HCV) infection
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Active infection with hepatitis C virus (HCV)
Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Patients with a history of hepatitis B virus (HBV) are excluded
Positive for acute or chronic Hepatitis B virus (HBV) infection
Acute or chronic Hepatitis C virus (HCV) infection
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration
Active hepatitis C virus (HCV) or hepatitis B virus (HBV)
Known hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; patients with documented cure from HCV infection will be included
Has active co-infection with HBV and hepatitis D virus (HDV)
If positive for hepatitis B virus (HBV) exposure or prior infection, can continue to participate in trial with prophylactic entecavir (for HBV); if positive for hepatitis C virus (HCV) exposure or active infection, can participate in trial with monitoring for liver function abnormalities
Antiviral therapy for hepatitis C virus (HCV) and hepatitis B virus (HBV) is allowed, but patient should not be on interferon.
Hepatitis B virus (HBV) positive participants will be excluded
Patients with active hepatic disease, liver cirrhosis, or known hepatitis B virus (HBV)/hepatitis C virus (HCV) infection
Known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Participant is known to be positive for hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals (non-exclusionary medications) are not excluded.
Has known active hepatitis B without hepatitis B virus (HBV) treatment (HBV infection with ongoing HBV treatment is allowed); has persistent chronic hepatitis C infection (successfully treated hepatitis C virus [HCV] infection is allowed)
Known history of hepatitis B virus (HBV) or hepatitis C (HCV) infection
Evidence of uncontrolled viral infection including Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), Human Herpes Virus-6 (HHV-6), Hepatitis Virus (HBV), or Hepatitis C Virus (HCV) based on assessment by the treating physician.
mCRPC EXPANSION COHORT: Hepatitis B virus (HBV) -or hepatitis C virus (HCV)-positive patients are ineligible
Patients who test positive for hepatitis B virus (HBV) or hepatitis C virus (HCV)
For non-HCC, there must not be acute or chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
PHASE I STUDY ELIGIBILITY CRITERIA: \r\nHepatitis B virus (HBV)-or hepatitis C virus (HCV)-positive patients are ineligible
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Active Epstein-Barr virus (EBV), hepatitis B virus (HBV) or hepatitis C virus (HCV)
Active hepatitis B virus (HBV) infection
Known history of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Known hepatitis B virus (HBV) or hepatitis C virus (HBV) infection
Patients with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infections
Patients with evidence of hepatitis C virus (HCV) or hepatitis B virus (HBV) infection must have no clinical evidence of cirrhosis
Hepatitis B virus (HBV) or untreated systemic infection
Has controlled infection by Hepatitis B Virus (HBV).
Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or at risk for HBV reactivation. Subjects whose immune status is unknown or uncertain must have results confirming immune status before enrollment.
Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to registration
Patients must NOT have liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh Class C); NOTE: A detailed assessment of hepatitis B/C medical history and risk factors must be done at screening for all patients; hepatitis B virus (HBV) and hepatitis C virus (HCV) testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection
Positive hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection at screening
HIV, hepatitis B virus (HBV), or hepatitis C virus (HCV) infection
Known acute or chronic-active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Has untreated active Hepatitis B virus (HBV)
Known HIV infection, or hepatitis B virus (HBV) or hepatitis C virus (HCV) viremia or at risk for HBV reactivation
Positive test results for chronic hepatitis B infection and hepatitis C virus (HCV)
Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection requiring treatment or have an active infection that is clinically serious in the investigator's opinion.
Patients who test positive for hepatitis B virus (HBV) or hepatitis C virus (HCV)
For gastric/GEJ and NSCLC participants, has chronic hepatitis B or hepatitis C infection. (For HCC participants, those with chronic hepatitis B virus [HBV] infection with a negative HBV deoxyribonucleic acid [DNA] test and who are on antiviral therapy, and those with chronic hepatitis C virus [HCV] infection are eligible)
Subjects with known active hepatitis B virus (HBV) and hepatitis C virus (HCV) infection
Patient has acute viral hepatitis or a history of chronic or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Documentation on hepatitis B virus (HBV) and hepatitis C virus (HCV) serology is required
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Patients must not have an active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
Patients who test positive for hepatitis B virus (HBV) or hepatitis C virus (HCV)
Patients with a known history of infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
Liver disease: Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection or risk of reactivation.
Positive hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection at screening
Positive serology test for hepatitis B virus (HBV), hepatitis C virus (HCV), or active tuberculosis
Known history of, or active hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosis
Subjects must meet the protocol-defined criteria for both hepatitis B virus (HBV) and hepatitis C virus (HCV) status
Known infection with hepatitis B virus (HBV) and hepatitis C virus (HCV); testing may have been done up to 3 months prior to treatment
Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)
Positive test results for chronic hepatitis B virus (HBV) infection or for hepatitis C virus (HCV) antibody
Patients with active or chronic hepatitis C virus (HCV)
Patients must be on antiviral therapy per the local standard of care if active or occult hepatitis B (hepatitis B virus [HBV]) infection; patients with active hepatitis C (hepatitis C virus [HCV]) may not be antiviral therapy
Patient is known to have a history of active or chronic infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests
Ongoing hepatitis B virus (HBV) infection
Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection that requires treatment or at risk for HBV reactivation.
Known hepatitis A virus (HAV), hepatitis B virus (HBV) or hepatitis C virus (HCV) positivity with evidence of ongoing infection.
Patients with known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are not eligible
NOTE: Patients with chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection may enroll if other laboratory criteria are met; those with HBV surface antigen positivity may enroll only if maintained on appropriate suppressive antiviral therapy for the duration of enrollment in the trial
Active chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, active HIV, or cytomegalovirus (CMV) infection.
Known, active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
